Skip to main content
Erschienen in: American Journal of Clinical Dermatology 2/2000

01.03.2000 | Review Article

Radiation-Recall Skin Disorders Associated With the Use of Antineoplastic Drugs

Pathogenesis, Prevalence, and Management

verfasst von: Dr Winnie Yeo, Philip J. Johnson

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 2/2000

Einloggen, um Zugang zu erhalten

Abstract

Radiation-recall dermatitis is the occurrence, with subsequent administration of cytotoxic chemotherapy, of an acute inflammatory toxicity in a previously quiescent radiation field. It may occur from days to weeks, and sometimes years, after the radiation therapy. The precise mechanism is unknown. One hypothesis suggests that the initial radiation therapy leads to a depletion of tissue stem cells within the irradiated field and that subsequent cytotoxic chemotherapy exposure causes a ‘remembered’ reaction among the remaining surviving cells. An alternative proposition suggests that radiation induces heritable mutations within surviving cells, which then produce a subgroup of defective stem cells that are unable to tolerate the second insult of chemotherapy. Recently, ataxia telangiectasia gene mutation and protein kinase deficiency have been associated with patients who have increased susceptibility to severe radiation-induced skin toxicity.
Most of the lesions will heal with supportive treatment. Although some reports have noted that radiation-recall dermatitis recurred with subsequent continued administration of the same chemotherapeutic agent, such experience is not universal. At present, a decision as to whether the same chemotherapeutic agent can be continued will usually be determined by the severity of the initial reaction, the chemoresponsiveness of the tumor to this particular agent, the individual patient’s wishes, and a clinical judgment that takes into account the availability of alternative therapy.
Literatur
1.
Zurück zum Zitat Eifel P.J., McClure S. Severe chemotherapy-induced recall of radiation mucositis in a patient with non-Hodgkin’s lymphoma of Waldeyer’s ring [letter]. Int J Radiat Oncol Biol Phys 1989; 17: 907–908PubMedCrossRef Eifel P.J., McClure S. Severe chemotherapy-induced recall of radiation mucositis in a patient with non-Hodgkin’s lymphoma of Waldeyer’s ring [letter]. Int J Radiat Oncol Biol Phys 1989; 17: 907–908PubMedCrossRef
2.
Zurück zum Zitat Mcinerney D.P., Bullimore J. Reactivation of radiation pneumonitis by adriamycin.Br J Radiol 1977; 50: 224–227CrossRef Mcinerney D.P., Bullimore J. Reactivation of radiation pneumonitis by adriamycin.Br J Radiol 1977; 50: 224–227CrossRef
3.
Zurück zum Zitat Cassady J.R., Richter M.T., Piro A.J., et al. Radiation-adriamycin interactions: preliminary clinical observations. Cancer 1975; 36: 946–949PubMedCrossRef Cassady J.R., Richter M.T., Piro A.J., et al. Radiation-adriamycin interactions: preliminary clinical observations. Cancer 1975; 36: 946–949PubMedCrossRef
4.
Zurück zum Zitat Kellie S.J., Plowman P.N., Malpas J.S. Radiation recall and radiosensitization with alkylating agents. Lancet 1987; I (8542): 1149–1150CrossRef Kellie S.J., Plowman P.N., Malpas J.S. Radiation recall and radiosensitization with alkylating agents. Lancet 1987; I (8542): 1149–1150CrossRef
5.
Zurück zum Zitat Donaldson S.S., Glick J.M., Wilbur J.R. Adriamycin activating a recall phenomenon after radiation therapy. Ann Intern Med 1974; 81: 407–408PubMed Donaldson S.S., Glick J.M., Wilbur J.R. Adriamycin activating a recall phenomenon after radiation therapy. Ann Intern Med 1974; 81: 407–408PubMed
6.
Zurück zum Zitat Redpath J.L., Cloman M. The effect of adriamycin and actinomycin D on radiation-induced skin reactions in mouse feet. Int J Radiat Oncol Biol Phys 1979; 5: 483–486PubMedCrossRef Redpath J.L., Cloman M. The effect of adriamycin and actinomycin D on radiation-induced skin reactions in mouse feet. Int J Radiat Oncol Biol Phys 1979; 5: 483–486PubMedCrossRef
7.
Zurück zum Zitat D’Angio G.J., Farber S., Maddock C.L. Potentiation of X-ray effects by actinomycin D. Radiology 1959; 73: 175–177PubMed D’Angio G.J., Farber S., Maddock C.L. Potentiation of X-ray effects by actinomycin D. Radiology 1959; 73: 175–177PubMed
8.
Zurück zum Zitat Pui C.H., de Graaf S.S.N., Dow L.W., et al. Phase 1 clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. Cancer Res 1998; 48: 5348–5352 Pui C.H., de Graaf S.S.N., Dow L.W., et al. Phase 1 clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. Cancer Res 1998; 48: 5348–5352
9.
Zurück zum Zitat Steizer K.J., Griffin T.W., Koh W.J. Radiation recall skin toxicity with bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency syndrome.Cancer 1993; 71: 1322–1325CrossRef Steizer K.J., Griffin T.W., Koh W.J. Radiation recall skin toxicity with bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency syndrome.Cancer 1993; 71: 1322–1325CrossRef
10.
Zurück zum Zitat Von Essen C.F., Kilgerman M.M. Calbresi P. Radiation and 5-fluorouracil: a controlled clinical study. Radiology 1963; 81: 1018–1027 Von Essen C.F., Kilgerman M.M. Calbresi P. Radiation and 5-fluorouracil: a controlled clinical study. Radiology 1963; 81: 1018–1027
11.
Zurück zum Zitat Nemechek P.M., Corder M.C. Radiation recall associated with vinblastine in a patient treated for Kaposi sarcoma related with Acquired Immune Deficiency Syndrome. Cancer 1992; 70: 1605–1606PubMedCrossRef Nemechek P.M., Corder M.C. Radiation recall associated with vinblastine in a patient treated for Kaposi sarcoma related with Acquired Immune Deficiency Syndrome. Cancer 1992; 70: 1605–1606PubMedCrossRef
12.
Zurück zum Zitat Sears M.E. Erythema in areas of previous irradiation in patients treated with hydroxyurea (NSC-32065). Cancer Chemother Rep 1964; 40: 31–32PubMed Sears M.E. Erythema in areas of previous irradiation in patients treated with hydroxyurea (NSC-32065). Cancer Chemother Rep 1964; 40: 31–32PubMed
13.
Zurück zum Zitat Jolivet J., Landry L., Pinard M.F., et al. A Phase 1 study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. Cancer Chemother Pharmacol 1987; 20: 169–172PubMedCrossRef Jolivet J., Landry L., Pinard M.F., et al. A Phase 1 study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. Cancer Chemother Pharmacol 1987; 20: 169–172PubMedCrossRef
14.
Zurück zum Zitat Fontana J.A. Radiation recall associated with VP-16-213 therapy. Cancer Treat Rep 1979; 63: 224–225PubMed Fontana J.A. Radiation recall associated with VP-16-213 therapy. Cancer Treat Rep 1979; 63: 224–225PubMed
15.
Zurück zum Zitat Phillips K.A., Urch M., Bishop J.F. Radiation-recall dermatitis in a patient treated with paclitaxel. J Clin Oncol 1995; 13: 305PubMed Phillips K.A., Urch M., Bishop J.F. Radiation-recall dermatitis in a patient treated with paclitaxel. J Clin Oncol 1995; 13: 305PubMed
16.
Zurück zum Zitat Shenkier T., Gelmon K. Paclitaxel and radiation-recall dermatitis. J Clin Oncol1994; 12: 439 Shenkier T., Gelmon K. Paclitaxel and radiation-recall dermatitis. J Clin Oncol1994; 12: 439
17.
Zurück zum Zitat Yeo W., Leung S.F., Johnson P.J. Radiation-recall dermatitis with docetaxel: establishment of a requisite radiation threshold. Eur J Cancer 1997; 33 (4): 698–699PubMedCrossRef Yeo W., Leung S.F., Johnson P.J. Radiation-recall dermatitis with docetaxel: establishment of a requisite radiation threshold. Eur J Cancer 1997; 33 (4): 698–699PubMedCrossRef
18.
Zurück zum Zitat Philips T.L., Fu K.K. Quantification of combined radiation therapy and chemotherapy affects on critical normal tissues. Cancer 1976; 37: 1186–1200CrossRef Philips T.L., Fu K.K. Quantification of combined radiation therapy and chemotherapy affects on critical normal tissues. Cancer 1976; 37: 1186–1200CrossRef
19.
Zurück zum Zitat Fu K.K. Normal tissue effects of combined radiotherapy and chemotherapy for head and neck cancer. Front Radiat Ther Oncol 1979; 13: 113–132 Fu K.K. Normal tissue effects of combined radiotherapy and chemotherapy for head and neck cancer. Front Radiat Ther Oncol 1979; 13: 113–132
20.
Zurück zum Zitat Cantril S.T. Audience interaction. Front Radiat Ther Oncol 1979; 13: 145–146 Cantril S.T. Audience interaction. Front Radiat Ther Oncol 1979; 13: 145–146
21.
Zurück zum Zitat Danjoux C.E. Delayed complications following combination of radiation and chemotherapy.Int J Radiat Oncol Biol Phys 1979; 5: 441–443PubMedCrossRef Danjoux C.E. Delayed complications following combination of radiation and chemotherapy.Int J Radiat Oncol Biol Phys 1979; 5: 441–443PubMedCrossRef
22.
Zurück zum Zitat Philips T.L., Wharam M.D., Margolis L.W. Modification of radiation injury to normal tissues by chemotherapeutic agents. Cancer 1975; 34: 1678–1684CrossRef Philips T.L., Wharam M.D., Margolis L.W. Modification of radiation injury to normal tissues by chemotherapeutic agents. Cancer 1975; 34: 1678–1684CrossRef
23.
Zurück zum Zitat Busch D. Genetic susceptibility to radiation and chemotherapy injury: diagnosis and management. Int J Radiat Oncol Biol Phys 1994; 30: 997–1002PubMedCrossRef Busch D. Genetic susceptibility to radiation and chemotherapy injury: diagnosis and management. Int J Radiat Oncol Biol Phys 1994; 30: 997–1002PubMedCrossRef
24.
Zurück zum Zitat West C.M., Elyan S.A., Berry P., et al. A comparison of the radiosensitivity of lymphocytes from normal donors, cancer patients and individuals with ataxiatelangiectasia (A-T) and A-T heterozygotes. Int J Radiat Oncol Biol Phys 1995; 68: 197–203 West C.M., Elyan S.A., Berry P., et al. A comparison of the radiosensitivity of lymphocytes from normal donors, cancer patients and individuals with ataxiatelangiectasia (A-T) and A-T heterozygotes. Int J Radiat Oncol Biol Phys 1995; 68: 197–203
25.
Zurück zum Zitat Jongmans W., Artuso M., Vuillaume M., et al. The role of ataxia-telangiectasia and the DNA-dependent protein kinase in the p53-mediated cellular response to ionizing radiation. Oncogene 1996; 13: 1133–1138PubMed Jongmans W., Artuso M., Vuillaume M., et al. The role of ataxia-telangiectasia and the DNA-dependent protein kinase in the p53-mediated cellular response to ionizing radiation. Oncogene 1996; 13: 1133–1138PubMed
26.
Zurück zum Zitat Opptiz U., Bernthaler U., Schindler D., et al. Sequence analysis of the ATM gene in 20 patients with RTOG grade 3 or 4 acute and/or late tissue radiation side effects. Int J Radiat Oncol Biol Phys 1999: 44: 981–988CrossRef Opptiz U., Bernthaler U., Schindler D., et al. Sequence analysis of the ATM gene in 20 patients with RTOG grade 3 or 4 acute and/or late tissue radiation side effects. Int J Radiat Oncol Biol Phys 1999: 44: 981–988CrossRef
27.
Zurück zum Zitat Tan C.T.C., Dargeon H.W., Burchenal J.H. The effect of actinomycin D on cancer in childhood. Pediatric 1959; 24: 544–561 Tan C.T.C., Dargeon H.W., Burchenal J.H. The effect of actinomycin D on cancer in childhood. Pediatric 1959; 24: 544–561
28.
Zurück zum Zitat Seymour C.B., Mothersill Q., Alper T. High yields of lethal mutations in somatic mammalian cells that survive ionizing radiation. Int J Radiat Biol 1986; 50: 167–179CrossRef Seymour C.B., Mothersill Q., Alper T. High yields of lethal mutations in somatic mammalian cells that survive ionizing radiation. Int J Radiat Biol 1986; 50: 167–179CrossRef
29.
Zurück zum Zitat Hellman S., Botnick L.E. Skin cell depletion. an explanation of the late effects of cytotoxins. Int J Radiat Oncol Biol Phys 1977; 2: 181–184PubMedCrossRef Hellman S., Botnick L.E. Skin cell depletion. an explanation of the late effects of cytotoxins. Int J Radiat Oncol Biol Phys 1977; 2: 181–184PubMedCrossRef
30.
Zurück zum Zitat Tsichler R.B., Schiff P.B., Geard C.R., et al. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992; 22: 613–617CrossRef Tsichler R.B., Schiff P.B., Geard C.R., et al. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992; 22: 613–617CrossRef
31.
Zurück zum Zitat Kitani H., Kosaka T., FukMara T., et al. The ‘recall effect’ in radiotherapy: is subeffective, reparable damage responsible? Int J Radiat Oncol Biol Phys 1990; 18: 689–695PubMedCrossRef Kitani H., Kosaka T., FukMara T., et al. The ‘recall effect’ in radiotherapy: is subeffective, reparable damage responsible? Int J Radiat Oncol Biol Phys 1990; 18: 689–695PubMedCrossRef
Metadaten
Titel
Radiation-Recall Skin Disorders Associated With the Use of Antineoplastic Drugs
Pathogenesis, Prevalence, and Management
verfasst von
Dr Winnie Yeo
Philip J. Johnson
Publikationsdatum
01.03.2000
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 2/2000
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200001020-00006

Weitere Artikel der Ausgabe 2/2000

American Journal of Clinical Dermatology 2/2000 Zur Ausgabe

Practical Dermatology

Diagnosing Superficial Mycoses

Adis New Drug Profile

Topical Aminolevulinic Acid HCl

Review Article

Alopecia Areata

Practical Dermatology

Diabetic Foot Ulcers

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.